You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞銀首予翰森製藥(03692.HK)「買入」評級 目標價18.1元
阿思達克 01-04 11:15
瑞銀發表研究報告,首予翰森製藥(03692.HK)「買入」評級及目標價18.1元。該行表示,翰森製藥是一間創新驅動的製藥公司,在腫瘤、抗感染、中樞神經系統(CNS)疾病和代謝疾病等治療領域建立了強大的影響力,認為集團有6種新藥獲批,58種候選新藥,有望抓住創新療法的市場機遇。 該行預計,集團的總收入將從2021年的99億元人民幣,增加到2026年的156億元人民幣,複合年增長率為9.4%,主要受新藥收入強勁增長的推動。該行估計,其新藥收入將從2021年的42億元人民幣,提升至2026年達到130億元人民幣,貢獻率從42.3%擴大到83.2%。對於仿製藥,料國家藥品集中採購(GPO)的下行風險可控,預期仿製藥收入在2026年後維持於約26億元人民幣。另外,該行料集團的全球商業潛力將逐步釋放,其於英國和歐盟的營銷授權申請正處於審查階段,預計2027年或會向美國提交監管文件。 該行預期集團2022至24年的每股盈利複合年增長率為14.5%,股本回報率增長50個基點,主要是受獲批新藥銷售增長的推動。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account